PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.

Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.

  Tue - Oct 27      Wed - Oct 28      Thu - Oct 29      Fri - Oct 30   

WEDNESDAY, OCTOBER 28

10:00 - 11:30 AM
PLENARY SESSION
PLENARY 2: KEY PERSPECTIVES ON SAFE AND EFFECTIVE ANTICOAGULANT THERAPY
Chair/Organizer: Anne Rose, Christine Guelcher

This Plenary session will address what are widely viewed as the most important issues for safe and effective anticoagulation therapy. The session will include an expert overview of current and emerging anticoagulant therapies, the public health approach to ensuring anticoagulant medication safety, and issues to consider to minimize both thrombotic and bleeding complications for patients undergoing surgery.



ANTICOAGULANT TARGETS: OVERVIEW OF CURRENT AND EMERGING THERAPIES
Jeff Weitz. McMaster University


THE IMPORTANCE OF PATIENT SAFETY CONSIDERATIONS: ANTICOAGULANTS PLACE IN THE PUBLIC HEALTH APPROACH TO MEDICATION SAFETY
Charles (Kurt) Mahan. Presbyterian Healthcare Services


MINIMIZING THROMBOTIC AND BLEEDING COMPLICATIONS IN THE SETTING OF SURGERY
PJ Devereaux. McMaster University

12:15 - 1:15 PM
SATELLITE SYMPOSIUM
CORPORATE LUNCH SYMPOSIUM: DOUBLE FEATURE: OBESITY IN HEMOPHILIA AND A TREATMENT OPTION FOR HEMOPHILIA A

Supported by: Novo Nordisk Pharmaceuticals, Inc.

The first part is an interactive program discussing the importance of managing obesity in the hemophilia community. Managing obesity is one of the toughest challenges for health care professionals in general and is often overlooked. This program will feature a discussion on obesity as a disease and how obesity impacts people with hemophilia. Results from a study designed to understand the barriers to initiating and maintaining weight loss in obese patients with hemophilia and to identify insights on the unique challenges of these patients from the perspective of health care professionals will be covered. In the second part, the program will feature aspects of the pathfinder clinical trial program and information on a factor VIII extended half-life product.

The program is being moderated by Dr. Stephanie Seremetis and will feature Dr. Meera Chitlur, Dr. Miguel Escobar and Dr. Anthony Auriemma.

Please see Prescribing Information

We kindly ask that you take a few minutes to complete the survey at end of the presentation



CORPORATE LUNCH SYMPOSIUM: HEMOPHILIA RESEARCH IN THE 21ST CENTURY

Sponsored By: Sanofi Genzyme

In this symposium, we will discuss a diverse range of possible approaches to managing hemophilia. We will reexamine what potential outcomes can be achieved for people with hemophilia and consider how we can support our patients on a path toward normalized hemostasis and quality of life.


2:00 - 3:30 PM
HEMOSTASIS / LABORATORY
EVALUATING FOR VON WILLEBRAND DISEASE
Chair/Organizer: William Nichols

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



DIAGNOSTIC TESTING FOR VON WILLEBRAND DISEASE: TRENDS AND INSIGHTS FROM EXTERNAL QUALITY ASSESSMENTS OF NORTH AMERICAN LABORATORY PRACTICES
Jameel Abdulrehman. University Health Network


ASSESSMENT OF CHILDREN FOR VON WILLEBRAND DISEASE: NEW EVIDENCE ON HOW MANY TIMES WE NEED TO TEST
Bhavya Doshi. Children's Hospital of Philadelphia


GENETIC TESTING FOR VON WILLEBRAND DISEASE. UPDATE ON WHEN IT IS USEFUL
Veronica Flood. Medical College of Wisconsin

2:00 - 3:30 PM
BASIC SCIENCE
NEW INSIGHTS ON COAGULATION
Chair/Organizer: Nicole Zantek, Muriel Maurer

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



NEW INSIGHTS ON FACTOR XIII AND THROMBOSIS
Muriel Maurer. University of Louisville


ANTI-INFLAMMATORY EFFECTS OF FVIIA
LVM Rao. The University of Texas Health Science Center at Tyler


INITIATION OF BLOOD COAGULATION
James Morrissey. University of Michigan Medical School

2:00 - 3:30 PM
THROMBOSIS
THE CHANGING LANDSCAPE OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM
Chair/Organizer: James Douketis

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



PRIMARY VTE PROPHYLAXIS IN CANCER PATIENTS
Marc Carrier. Ottawa Hospital Research Institute


TREATMENT OF CANCER-ASSOCIATED VTE, INCLUDING SPECIAL AND DIFFICULT PATIENT POPULATIONS.
Michael Streiff. Johns Hopkins University School of Medicine


CLINICAL CONTROVERSIES IN TREATING THROMBOSIS
Sam Schulman. McMaster University

4:15 - 5:45 PM
THROMBOSIS
DTI USE
Chair/Organizer: Luis Meillon, Teresa Bordeaux

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



DTI USE FOR ATYPICAL VTE (SPLANCHNIC BED, CEREBRAL VEIN THROMBOSIS) AND FOR HIT(T)
Rachel Rosovsky. Massachusetts General Hospital


DTI USE IN LVADS, ECMO, CARDIAC CATH
Jerrold Levy. Duke University School of Medicine


DTI USE IN PEDIATRICS
Shannon Carpenter. Children's Mercy Hospital

4:15 - 5:45 PM
HEMOSTASIS
EMERGING ISSUES IN BLEEDING DISORDERS
Chair/Organizer: Michelle Witkop

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



GENETIC TESTING FOR CONGENITAL THROMBOCYTOPENIA SYNDROMES
Brian Branchford. University of Colorado School of Medicine and Children's Hospital Colorado


TREATING PAIN IN PATIENTS WITH BLEEDING DISORDERS
Tyler Buckner. University of Colorado School of Medicine


ANTICOAGULATION FOR PATIENTS WITH BLEEDING DISORDERS (COVERS VTE PROPHY IN ORTHO PROCEDURES, RX OF AF, CAD IN BLEEDING DISORDER PTS AND PVT IN CIRRHOTICS)
Craig Kessler. Georgetown University Medical Center

4:15 - 5:45 PM
LABORATORY / BASIC SCIENCE
UPDATE ON THROMBOTIC MICROANGIOPATHIES
Chair/Organizer: Charles Eby, Marian Rollins Raval

Welcome to the Live Session. The live stream will appear below at the scheduled time for all logged-in registrants to view. If you see an Ask a Question option to the right of the presentation, we highly encourage questions during the live events to facilitate scheduled Q&A portions of the session. Please be sure to get your questions in early. Theater Mode offers you the option to view a larger version of the presentation. Once the session concludes, a recording will be available for on-demand access if this session has been approved for enduring content posting.



OVERVIEW ON THROMBOTIC THROMBOCYTOPENIC PURPURA INCLUDING THE IMPORTANCE OF ADAMTS13 ASSAYS FOR DIAGNOSIS
Sateesh Chonat. Emory University and Children's Healthcare of Atlanta


NEW INSIGHTS ON THE CONTRIBUTIONS OF ADAMTS13 AND COMPLEMENT TO TTP PATHOGENESIS FROM EXPERIMENTAL MODELS
X. Long Zheng. The University of Alabama at Birmingham


CLINICAL AND LABORATORY CONSIDERATIONS FOR THE LONG TERM FOLLOWUP AND TREATMENT OF TTP
James George. University of Oklahoma Health Sciences Center

6:00 - 7:00 PM
SATELLITE SYMPOSIUM
CORPORATE DINNER SYMPOSIUM: CLINICAL INSIGHTS IN VTE: TREATMENT AND RISK REDUCTION THROUGH PROPHYLAXIS (LIVE ONLY - NOT RECORDED)

Sponsored by: Janssen Pharmaceuticals, Inc.

Speaker: Samuel A. Berkman, MD, FACP
Clinical Professor of Medicine, Division of Hematology-Oncology
UCLA Medical Center
Beverly Hills, California

This lecture will discuss venous thromboembolism (VTE) prophylaxis, as well as treatment options for patients with deep vein thrombosis and/or pulmonary embolism, and how these treatment options may reduce the risk of recurrent thrombotic events.


6:15 - 7:00 PM
EVENT/OTHER
THSNA NETWORKING HAPPY HOUR: TRANSITION TO PRACTICE DISCUSSION FORUM FOR TRAINEES AND THOSE IN THE FIRST FEW YEARS OF PRACTICE.
Chair/Organizer: Roona Sinha

This will be an open discussion for trainees and those new in practice to discuss issues they are having or they anticipate having with regards to transition to practice, how to navigate being a staff physician, and how to make the most of the THSNA conference as a transitioning physician!


7:00 - 8:00 PM
SHORT TALKS
BASIC SCIENCE OF THROMBOSIS/ANTICOAGULATION


EXTRACELLULAR VESICLES DERIVED FROM RED BLOOD CELLS ACTIVATE MICROVASCULAR ENDOTHELIAL CELLS AND RESULT IN RED BLOOD CELL ADHESION IN SICKLE CELL DISEASE
Ran An1, Yuncheng Man1, Jane A. Little2, Umut A. Gurkan1. 1Case Western Reserve University, Cleveland, OH, USA. 2The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA


COMBINATION OF HEPARIN AND A FX/FXA APTAMER TO REDUCE THROMBIN GENERATION IN MODELS OF CARDIOPULMONARY BYPASS
Charlene V. Chabata1, 2, James W. Frederiksen2, Ruwan Gunaratne3, Bruce A. Sullenger1, 2. 1Duke University, Department of Pharmacology and Cancer Biology, Durham, NC, USA. 2Duke University, Department of Surgery, Durham, NC, USA. 3Stanford University, School of Medicine, Palo Alto, CA, USA


DIFFERENTIAL NEUTRALIZATION OF APIXABAN, BETRIXABAN, EDOXABAN, AND RIVAROXABAN BY ANDEXANET ALFA AS MEASURED BY WHOLE BLOOD THROMBOELASTOGRAPHIC ANALYSIS
Siddharth Mehrotra1, Debra Hoppensteadt1, Walter Jeske1, Omer Iqbal1, Alfonso Tafur2, Bruce Lewis1, Jawed Fareed1. 1Loyola University Medical Center, Maywood, IL, USA. 2Northshore Health Systems, Skokie, IL, USA


INHIBITORS AGAINST PROCOAGULANT AND ANTIFIBRINOLYTIC PROPERTIES OF EXTRACELLULAR NUCLEIC ACIDS
Sreeparna Vappala1, 2, 8, Manu Thomas Kalathottukaren1, 2, 8, Srinivas Abbina1, 2, 8, Chanel La1, 3, 8, Libin Abraham4, 8, Iren Constantinescu1, 2, 8, Charles A Haynes1, 5, 8, Edward M Conway1, 6, 8, Jayachandran N Kizhakkedathu1, 2, 3, 7, 8. 1Centre for Blood Researc, Vancouver, BC, Canada. 2Department of Pathology and Laboratory medicine, Vancouver, BC, Canada. 3Department of Chemistry, Vancouver, BC, Canada. 4Microbiology and Immunology, Vancouver, BC, Canada. 5Chemical a Biological Engineering, Vancouver, BC, Canada. 6Department of Medicine, Vancouver, BC, Canada. 7The School of Biomedical Engineering, Vancouver, BC, Canada. 8University of British Columbia, Vancouver, BC, Canada


LABORATORY 2


ORDER SET MODIFICATION PROMOTES EFFECTIVE LABORATORY TEST UTILIZATION IN THE DIAGNOSIS OFHIT
Michael Kimbrell, John Larson, Mikhail Akbashev. Emory University Department of Medicine, Atlanta, GA, USA


UNRELIABILITY OF ACTIVATED PARTIAL THROMBOPLASTIN TIME TO MONITOR BIVALIRUDIN THERAPY IN PEDIATRIC EXTRACORPOREAL LIFE SUPPORT
Vadim Kostousov1, 2, Karen Bruzdoski1, Lisa Hensch1, 2, Shiu-Ki Rocky Hui1, 2, Jun Teruya1, 2. 1Texas Children's Hospital, Houston, TX, USA. 2Baylor College of Medicine, Houston, TX, USA


SEROTONIN RELEASE ASSAY BY LIQUID MASS SPECTROMETRY: A COMPARATIVE LABORATORY METHODS STUDY
Rachel R Leger1, Jennifer A Faber1, Deepti M Warad1, Ravinder J Singh1, Jansen N Seheult2, Rajiv K Pruthi1, Dong Chen1. 1Mayo Clinic, Rochester, MN, USA. 2University of Pittsburgh Medical Center, Pittsburgh, PA, USA


CHROMOGENIC BETHESDA ASSAY PERFORMANCE IN HEMOPHILIA A PATIENTS WITH AND WITHOUT EMICIZUMAB
Connie H Miller1, Brian Boylan1, Amanda B Payne1, Jennifer Driggers1, Christopher J Bean1, HIRS Investigators2. 1Centers for Disease Control and Prevention, Atlanta, GA, USA. 2See appendix, HIRS United States


BIOMARKERS OF INTRAVASCULAR COAGULATION AND FIBRINOLYSIS IN SEVERE SARS-COV-2 INFECTION (COVID-19)
Jansen N. Seheult1, 2, Michael P. Meyer2, Michelle N. Stram3, Andrea Cortese Hassett2, Alan Wells1, Haris Zia4, Alison Morris5, Janet S. Lee5, Bryan J. McVerry5, Matthew D. Neal6, Georgios Kitsios5, William Bain5. 1Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2Vitalant Specialty Labs - Coag a MID, Pittsburgh, PA, USA. 3Department of Forensic Medicine, New York University, New York, NY, USA. 4Internal Medicine Residency Program, University of Pittsburgh Medical Center McKeesport, Pittsburgh, PA, USA. 5Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 6Pittsburgh Trauma Research Center and Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA


PLATELETS AND VON WILLEBRAND FACTOR


ADVERSE BONE HEALTH AND WOUND HEALING OUTCOMES IN VON WILLEBRAND DISEASE
Divyaswathi Citla Sridhar1, 3, Yazan Abou-Ismail2, 3, Maria Pereda1, 3, Lalitha Nayak2, 3, Robert Sidonio Jr4, Sanjay Ahuja1, 3. 1Rainbow Babies a Children's Hospital, Cleveland, OH, USA. 2University Hospitals Cleveland Medical Center, Cleveland, OH, USA. 3Case Western Reserve University, Cleveland, OH, USA. 41Children, Atlanta, GA, USA


GENOTYPE VS PHENOTYPE:A CROSS-SECTIONAL STUDY EXAMINING THE INCIDENCE OF GENETIC VARIANTS IN PATIENTS WITH QUALITATIVE PLATELET DISORDERS
Kristina/M Haley, Stewart Worthington, Susan Lattimore, Mary Pat Bland, Jody Kujovich. Oregon Health a Science University, Portland, OR, USA


PLATELETS AS VERSATILE EFFECTORS OF THROMBOINFLAMMATION IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS
Anandi Krishnan1, Wenfei Du2, Cecelia Perkins3, Zhu Shen4, Jason Gotlib5, James Zehnder6. 1Pathology, Stanford, CA, USA. 2Statistics, Stanford, CA, USA. 3Hematology, Stanford United States. 4Statistics, Stanford, CA, USA. 5Hematology, Stanford, CA, USA. 6Hematology, Stanford, CA, USA


THROMBOSIS: RISKS


INCREASED RISK OF THROMBOSIS IN ALK-REARRANGED LUNG CANCER
Hanny Al-Samkari1, 2, Orly Leiva2, 3, Ibiayi Dagogo-Jack1, 2, Alice Shaw1, 2, Pavan K. Bendapudi1, 2, Jean M. Connors2, 4. 1Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA. 2Harvard Medical School, Boston, MA, USA. 3Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 4Hematology Division, Brigham and Women's Hospital, Boston, MA, USA


EFFECT OF RACE/ETHNICITY ON THE RISK OF CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM FOR THREE COMMON CANCERS
Tatini Datta, Ann Brunson, Anjlee Mahajan, Theresa Keegan, Ted Wun. Center for Oncology Hematology Outcomes Research and Training (COHORT), Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento, CA, USA


REDUCED CALF MUSCLE PUMP FUNCTION IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM AND MORTALITY
Damon / E Houghton, Aneel Ashrani, David Liedl, Ramila Mehta, Paul Wennberg, Waldemar Wysokinski, Thom Rooke, Robert McBane. Mayo Clinic, Rochester, MN, USA


LOW BLEEDING RISK PROCEDURES: SHOULD WE LET DOAC BE?
Muhammad A. Sheikh1, Xiaowen Kong2, Brian Haymart2, Xiaokui Gu2, Scott Kaatz3, Gregory Krol3, Jay Kozlowski4, Musa Dahu5, Mona Ali6, Steven Almany7, Eva Kline-Rogers2, James Froehlich2, Geoffrey D. Barnes2. 1Division of Hospital Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 2Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. 3Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA. 4Department of Cardiovascular Medicine, Huron Valley Sinai Hospital, Commerce Township, MI, USA. 5Heart and Vascular Institute, Spectrum Health System, Grand Rapids, MI, USA. 6Department of Pharmacy, Beaumont Hospital, Royal Oak, MI, USA. 7Department of Internal Medicine, Beaumont Health, Oakland University School of Medicine, Royal Oak, MI, USA


CREATION OF A REAL-TIME RISK PREDICTION MODEL FOR PEDIATRIC THROMBOSIS EVENTS
Shannon C. Walker1, C. Buddy Creech1, Henry J. Domenico2, Daniel W. Byrne2, Allison P. Wheeler1, 2. 1Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, USA. 2Vanderbilt University Medical Center, Nashville, TN, USA

7:00 - 7:45 PM
POSTER SESSION
VIRTUAL POSTERS - BLOOD COAGULATION AND FIBRINOLYTIC FACTORS

Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the Ask a Question option. Note that all questions may not receive a response.



21

TRANSIENT GENE THERAPY TO DECREASE THE STABILITY OF THROMBI FOR COAGULOPATHY AND THROMBOSIS
Amy Strilchuk1, 2, Scott Meixner2, Joseph Palumbo3, Ed Conway2, Ed Pryzdial2, Pieter Cullis2, Christian Kastrup1, 2. 1Michael Smith Laboratories, Vancouver, BC, Canada. 2University of British Columbia, Vancouver, BC, Canada. 3Cancer and Blood Diseases Institute, Cincinnati Children, Cincinnati, OH, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


1

INFLUENCE OF DOAC REMOVE ON COAGULATION ASSAYS IN SAMPLES FROM PATIENTS ON ANTICOAGULATION
Zahra Al-Qawzai1, Nada Yartey2, Chris Dale2, Minal Dave2, Sean Platton2. 1Clinical Biochemistry Laboratory, Royal London Hospital, London, United Kingdom. 2Haemostasis Laboratory, Royal London Hospital, London, United Kingdom


2

RECOGNIZING REASONS OF UNWARRANTED COAGULATION TESTING IN MEDICALLY ILL PATIENTS - A SNEAK PEEK
Sidra Asad Ali, Amir Khan, Naila Noor. Patel Hospital, Karachi, Pakistan


3

IDENTIFY THE KNOWLEDGE, ATTITUDE AND PRACTICE OF HEALTHCARE PROVIDERS TOWARD PRESCRIBING FACTOR REPLACEMENT AT FEDERALLY FUNDED HEMOPHILIA TREATMENT CENTERS IN THE UNITED STATES.
Maya Bloomberg1, Krysten Sargenton1, Karina Gattamorta2, Debbie Anglade2. 1University of Miami Hemophilia Treatment Center, Miami, FL, USA. 2University of Miami School of Nursing a Health Studies, Miami, FL, USA


4

PROFILE OF INFLAMMATORY BIOMARKERS AND COAGULATION FACTORS IN END-STAGE RENAL DISEASE
Emily Bontekoe, Arjun Grewal, Vinod Bansal, Debra Hoppensteadt, Melissa Mazariegos, Jawed Fareed. Loyola University Chicago, Maywood, IL, USA


5

COAGULATION PROFILE DERANGEMENT AND DISEASE SEVERITY/SPECTRUM IN PEDIATRIC POPULATION
Asma N Cheema1, Syeda Saima Irshad2, Muhammad Aamer Sujjad1, Muhammad Gulsher1. 1Department of Pathology, Children's Hospital a The Institute of Child Health, Multan, Pakistan. 2Department of Pediatric medicine Children's Hospital a The Institute of Child Health, Multan, Pakistan


6

PERFORMANCE CHARACTERISTICS OF A CHROMOGENIC FACTOR VIII METHOD ON THE STA-R EVOLUTION XP
Ronda A Crist1, Daniel A Stephens1, George M Rodgers1, 2, 3, Jessica Corean1, 2, Karen A Moser1, 2, Kristi J Smock1, 2. 1ARUP Institute for Clinical and Experimental Pathologyr, Salt Lake City, UT, USA. 2Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. 3Division of Hematology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA


7

THE DEVELOPMENT AND IMPACT OF A HEMOSTATIC STEWARDSHIP PROGRAM AT TWO LARGE ACADEMIC MEDICAL CENTERS
Kathryn Dane, John Lindsley, Satish Shanbhag, Michael Streiff. The Johns Hopkins Hospital, Baltmore, MD, USA


8

ASSOCIATION OF HYPERCOAGULABLE STATE WITH CLINICAL SEVERITY OF SICKLE CELL DISEASE IN SUDANESE PATIENTS
Alaaeddin M. Elzubeir1, 2, Shima H. Elsheikh2, Tayseer A. Alabid2. 1University of Colorado Denver, Aurora, CO, USA. 2University of Khartoum, Khartoum, Sudan


9

EVALUATION OF A RAPID AUTOMATED CHEMILUMINESCENT ADAMTS13 ACTIVITY ASSAY FOR THE ACL ACUSTAR
R Fretwell, T Pitchford, SM Cooper, S Kitchen. Sheffield Teaching Hospitals, Sheffield, United Kingdom


10

VON WILLEBRAND DISEASE IN PREGNANCY AND THE USE OF EPIDURAL ANALGESIA
Maissaa Janbain, MD, Radia Ksayer, MD, Anna Swigert, BS. Tulane University School of Medicine, New Orleans, LA, USA


11

EFFECTS OF TAI CHI ON BALANCE IN INDIVIDUALS LIVING WITH HEMOPHILIA
Mark Krimmel1, Rebecca Kruse-Jarres2, Bruno Steiner3. 1Washington Center for Bleeding Disorders, Seattle, WA, USA. 2University of Washington, Seattle, WA, USA. 3Washington Center for Bleeding Disorders, Seattle, WA, USA


12

EFFECT OF HUMAN PLASMA ON EVALUATION OF COAGULATION FACTOR VIII PRODUCT PURITY BY WESTERN BLOT
Yideng Liang, Mohammad B Uddin, Alexey V Khrenov, Sergey S Akimov, Timothy K Lee, Mikhail V Ovanesov. U. S. Food and Drug Administration, Silver Spring, MD, USA


13

KNOCKDOWN OF HEPATIC TAFI OR A2AP BY GALNAC-SIRNA STRATEGY EXPEDITED THROMBOLYSIS IN A RODENT LARGE-VEIN ELECTROLYTIC INJURY MODEL
Jingxuan Liu1, Brian Cooley2, Akin Akinc1, Anna Borodovsky1, Patrick Haslett1. 1Alnylam Pharmaceuticals, Cambridge, MA, USA. 2University of North Carolina, Chapel Hill, NC, USA


14

UNRAVELLING THE ROLE OF THE FACTOR X GLA DOMAIN IN INITIATION OF THE CLOTTING CASCADE
Divyani Paul1, James Morrissey1, 2. 1Department of Biological Chemistry, Ann Arbor, MI, USA. 2Department of Internal Medicine, Ann Arbor, MI, USA


15

CRYOCHECK™ CHROMOGENIC FACTOR VIII: A NEW KIT FOR THE DETERMINATION OF FACTOR VIII:C ACTIVITY
Tara Quinton, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc, Dartmouth, NS, Canada


16

PERFORMANCE OF CRYOCHECK™ CHROMOGENIC FACTOR VIII IN THE RECOVERY OF FACTOR VIII REPLACEMENT THERAPIES
Tara Quinton, Karen M. Black, Ali Sadeghi-Khomami. Precision BioLogic Inc, Dartmouth, NS, Canada


17

DEVELOPMENT AND PERFORMANCE CHARACTERIZATION OF AN AUTOMATED CHROMOGENIC ASSAY FOR HUMAN FACTOR IX ACTIVITY
Narayanan Ramamurthy, Sean Duffin, Cheryl Kucharshi, Zach Vandertuin, Michael Morris. r2 Diagnostics Inc, Suoth Bend, IN, USA


18

MATHEMATICAL MODELING OF IMPACTS OF VARIABLE HEMATOCRIT AND BLOOD COLLECTION FILL VOLUME ON CITRATED PLASMA FOR COAGULATION TESTING
Jay S. Raval, Marian A. Rollins-Raval, Richard A. Marlar. University of New Mexico, Albuquerque, NM, USA


19

TRENDS IN D-DIMERS AND THROMBOSIS AMONG PATIENTS EVALUATED FOR COVID-19
Francois Rollin, Bhavin B Adhyaru, Afshan Idrees, Seema Tekwani, Mikhail Y Akbashev. Emory University School of Medicine, Atlanta, GA, USA


20

PHARMACOVIGILANCE OF VON WILLEBRAND FACTOR/COAGULATION FVIII COMPLEX (HUMAN)- 10 YEARS' EXPERIENCE
Claudio Sandoval, Azim Saifee, Dipen Patel, Huub Kreuwel. Octapharma USA, Hoboken, NJ, USA


22

EFFICACY AND SAFETY OF N8-GP FOR PROPHYLAXIS AND BLEED CONTROL IN US VS GLOBAL PATIENTS WITH HEMOPHILIA A: RESULTS FROM THE PATHFINDER CLINICAL PROGRAM
Allison P. Wheeler1, Miguel Escobar2, Susan Kearney3, Leslie Raffini4, Janice M. Staber5, Suchitra Acharya6, David L. Cooper7, Steven Lentz8. 1Vanderbilt University Medical Center, Vanderbilt University, Nashville, TN, USA. 2University of Texas Health Science Center, Houston, TX, USA. 3Children, Minneapolis, MN, USA. 4Children, Philadelphia, PA, USA. 5University of Iowa Stead Family Children, Iowa City, IA, USA. 6Cohen Children, New Hyde Park, NY, USA. 7Novo Nordisk Inc, Plainsboro, NJ, USA. 8University of Iowa, Iowa City, IA, USA


23

LEVERAGING TURBIDIMETRY AND THROMBOELASTOGRAPHY TO CHARACTERIZE FIBRIN FORMATION UNDER DIVERSE CLOTTING CONDITIONS
Ziqian Zeng1, 2, Mahussi Fagnon1, Tanmaye Nallan Chakravarthula1, 2, Nathan / J Alves1, 2. 1Indiana University School of Medicine: Emergency Medicine, Indianapolis, IN, USA. 2Purdue University: Weldon School of Biomedical Engineering, West Lafayette, IN, USA


VIRTUAL POSTERS - DISORDERS OF COAGULATION OR FIBRINOLYSIS

Welcome to this Virtual Poster Session. You may view any poster by clicking on a presentation below. Note that you may also submit questions directly to the author of any presentation using the Ask a Question option. Note that all questions may not receive a response.



A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


2

RISK FACTORS AMONG OUTPATIENTS AND HOSPITALIZED PATIENTS WITH VTE USING POPULATION-BASED SURVEILLANCE DATA FROM TWO US COUNTIES 2012-2014
Karon Abe1, Alys Adamski1, Aaron Wendleboe2, Nimia Reyes1, Gary Raskob2, Thomas Ortel3. 1Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA. 2Hudson College of Public Health, University of Oklahoma Health Sciences, Norman, OK, USA. 3Division of Hematology, Duke University Medical Center Durham, NC, USA


3

LONG-TERM BLEEDING AND CONSUMPTION RATES OF PROPHYLAXIS WITH BAY 94-9027 IN ADOLESCENTS AND YOUNG ADULTS WITH HEMOPHILIA A IN THE PROTECT VIII STUDY
Sanjay Ahuja1, Mindy L. Simpson2, Jonathan M. Ducore3, Olubunmi Afonja4, Inga Bayh5, Mark T. Reding6. 1Rainbow Babies a Children, Cleveland, OH, USA. 2Rush University Medical Center, Chicago, IL, USA. 3University of California Davis Medical Center, Sacramento, CA, USA. 4Bayer, Whippany, NJ, USA. 5Bayer, Wuppertal, Germany. 6University of Minnesota Medical Center, Minneapolis, MN, USA


4

EFFICACY AND SAFETY OF BAY 94-9027 PROPHYLAXIS IS SUSTAINED FOR UP TO >2 YEARS: OUTCOMES IN 23 PATIENTS AGED ≥12 YEARS IN THE PROTECT KIDS STUDY AND EXTENSION
Sanjay Ahuja1, Jonathan M. Ducore2, Olubunmi Afonja3, Maria Wang3, Bryce A. Kerlin4. 1Rainbow Babies a Children, Cleveland, OH, USA. 2University of California Davis Medical Center, Sacramento, CA, USA. 3Bayer, Whippany, NJ, USA. 4Nationwide Children's Hospital, Columbus, OH, USA


5

ICH IN FVII DEFICIENCY: DURATION OF PROPHYLAXIS?
Alyaa Al Mughairy1, 2, Vanessa Bouskil1, Melanie Jackson1, Caroline Malcolmson1, Ahmad Al Hunaiti1, Manuel Carcao1. 1Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. 2The Royal Hospital, Muscat, Oman


6

VENOUS THROMBOEMBOLISM IN MELANOMA PATIENTS: ANALYSIS FROM THE NATIONAL INPATIENT SAMPLE DATABASE
Hussam Alhasson1, Anas Saad 2, Yu Zhao1, Zimu Gong 3, Muneer Alhusseini4. 1Rochester Regional Health/ Unity Hospital, Rochester, NY, USA. 2Cleveland Clinic Foundation, Cleveland, OH, USA. 3AMITA Health St Joseph Hospital, Chicago, IL, USA. 4Ascension St John Hospital, Detroit, MI, USA


7

POPULATION PHARMACOKINETICS OF RECOMBINANT VON WILLEBRAND FACTOR IN PATIENTS WITH VON WILLEBRAND DISEASE OR SEVERE HEMOPHILIA A
Alexander Bauer1, Bettina Ploder1, Zhaoyang Li2, Bjorn Mellgard3, Sofia Friberg-Hietala4, Martin Wolfsegger1. 1Baxalta Innovations GmbH, a Takeda company, Vienna, Austria. 2Shire US Inc, a Takeda company, Cambridge, MA, USA. 3Baxalta US Inc, a Takeda company, Cambridge, MA, USA. 4Pharmetheus AB, Uppsala, Sweden


8

THE INTEGRATED ROLE OF C-REACTIVE PROTEIN, NITRIC OXIDE, DDIMER, MYELOPEROXIDASE, AND PLASMINOGEN ACTIVATOR INHIBITOR-1 IN THE PATHOGENESIS OF END STAGE RENAL DISEASE
Meriam Ben Hadj Tahar, Vinod Bansal, Emily Bontekoe, Alyssa Abrenica, Debra Hoppensteadt, Alek Druck, Jawed Fareed. Loyola University Medical Center, Maywood, IL, USA


9

ANTIHEMOPHILIC FACTOR (HUMAN) CHARACTERIZATION: FOCUS ON TTP TREATMENT
Benedetta Bonito1, Cristina Genuardo1, 2, Ilaria Nardini1, Andrea Caricasole1, Claudio Farina1, Novinyo S. Amega3, Filippo Mori1. 1Department of Research a Innovation, Kedrion SpA, Via di Fondovalle, Loc. Bolognana, Italy. 2Department of Pharmacy, Pisa, Italy. 3Department of Medical Affairs, Fort Lee, NJ, USA


10

DIFFERENTIAL FIBRINOLYSIS DYNAMICS IN PERIPARTUM WOMEN BASED ON THE ROUTE OF DELIVERY
Maria Cristina Bravo, Thomas Orfeo, Kelley McLean, Ira Bernstein, Kathleen Brummel-Ziedins. University of Vermont, Burlington, VT, USA


11

VALIDATION OF CHROMOGENIC FACTOR VIII ACTIVITY ASSAYS AT CHILDREN'S HOSPITAL LOS ANGELES (CHLA)
Joshua M. Brown, PhD1, Melissa Arevalo1, Desiree Tan-Castillo1, Edward Leung, PhD, DABCC, FAACC1, 2, Guy Young, MD1, 2, Maurice O'Gorman, MBA, MSc, PhD, D(ABMLI)1, 2. 1Children's Hospital Los Angeles, Los Angeles, CA, USA. 2University of Southern California Keck School of Medicine, Los Angeles, CA, USA


12

HIGH-PURITY PLASMA-DERIVED FACTOR X IS EFFECTIVE FOR SHORT-TERM PREVENTATIVE USE AND PERI-SURGICAL HEMOSTATIC COVER: RESULTS FROM A RETROSPECTIVE, OPEN-LABEL, COMPASSIONATE-USE STUDY OF PATIENTS WITH HEREDITARY FACTOR X DEFICIENCY
Martina Buehrlen1, Tiraje Celkan2, James N Huang3, Chioma Akanezi4, Sarale Russ4. 1Klinikum Bremen-Mitte, Prof-Hess-Kinderklinik, Bremen, Germany. 2Istanbul University Cerrahpasa School of Medicine, Fatih, Istanbul, Turkey. 3University of California San Francisco, Benioff Children, San Francisco, CA, USA. 4Bio Products Laboratory Ltd, Elstree, United Kingdom


13

QUALITY OF LIFE AND CLINICAL OUTCOMES FROM CHESS US+: A PATIENT-CENTRIC STUDY OF SEVERE HEMOPHILIA B IN THE US
Tom Burke1, Sohaib Asghar1, Jamie O'Hara1, 2, Eileen K. Sawyer3, Nanxin (Nick) Li3. 1HCD Economics, Daresbury, United Kingdom. 2Faculty of Health and Social Care, University of Chester, Chester, United Kingdom. 3uniQure Inc, Lexington, MA, USA


14

EFFICACY OF UPFRONT LOW DOSE COMBINED IMMUNOSUPPRESSION IN ACQUIRED HEMOPHILIA A: A SINGLE CENTER RETROSPECTIVE COHORT STUDY
Lorraine A. Cafuir, Duc Q. Tran, Anthony DeBalsi, Christine L. Kempton. Emory University, Atlanta, GA, USA


15

SUBDURAL HEMORRHAGE AND CEREBRAL SINOVENOUS THROMBOSIS: FREQUENCY AND ASSOCIATIONS WITH CLINICAL AND HISTORICAL FACTORS.
Shannon L Carpenter1, Mukta Sharma1, Terra Frazier1, Lauren Beslow2, Guillaume Sebire3, Michael Noetzel4, Brian Appavu5, James D Anderst1. 1Children's Mercy Hospital, Kansas City, MO, USA. 2Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3Montreal Children Hospital, Montreal, QC, Canada. 4Washington University, St. Louis, MO, USA. 5Phoenix Children's Hospital, Phoenix, AZ, USA


16

EXTERNAL QUALIFICATION OF THE WEB-ACCESSIBLE POPULATION PHARMACOKINETIC SERVICE - HEMOPHILIA (WAPPS-HEMO) MODELS FOR OCTOCOG ALFA (KOVALTRY) USING REAL PATIENT DATA
Pierre Chelle1, Dagmar Hajducek1, Mohammed Mahdi2, Stuart Young2, Alfonso Iorio3, Andrea Edginton1. 1School of Pharmacy, University of Waterloo, Waterloo, Canada. 2Bayer, Mississauga, Canada. 3McMaster-Bayer Endowed Research Chair for Clinical Epidemiology of Congenital Bleeding Disorders, Department of Medicine, Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada


17

SURGICAL SPLENECTOMY AND RISK OF VENOUS THROMBOEMBOLISM IN SICKLE CELL DISEASE
Jennifer Chen1, Manuela Plazas Montana2, Elizabeth Williams2, Payal Desai3, Joshua Field4, Sophie Lanzkron2, Jane Little5, Deepa Manwani6, Lynne Neumayer7, Rakhi P. Naik 2. 1The Johns Hopkins School of Medicine, Baltimore, MD, USA. 2Department of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 3The Ohio State University, Columbus, OH, USA. 4Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA. 5Department of Hematology and Oncology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. 6Department of Pediatrics, Albert Einstein College of Medicine, New York City, NY, USA. 7Department of Hematology Oncology, UCSF Benioff Children's Hospital and Research Center Oakland, Oakland, CA, USA


18

EMICIZUMAB IN ACQUIRED HEMOPHILIA A
Sheh-Li Chen1, Raj S Kasthuri2, Alice D Ma2, Stephan Moll2, Nigel S Key2. 1Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA. 2Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA


19

EMICIZUMAB AND TRAUMA: CASE REPORT OF FRACTURE, FASCIOTOMY AND SKIN GRAFTING IN A HEMOPHILIA PATIENT WITH HIGH TITER INHIBITOR
Daniel Choi, Maria Teresa DeSancho, Jeffery Laurence, Ilene Goldberg, Catherine McGuinn. Weill Cornell Medicine, New York, NY, USA


19

A PHASE 3B, OPEN-LABEL, MULTICENTER, CONTINUATION STUDY OF RURIOCTOCOG ALFA PEGOL PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A: CLINICAL OUTCOMES IN PATIENTS WITH TARGET JOINTS BY AGE GROUP
Pratima Chowdary1, Eric Mullins2, Barbara A. Konkle3, Catherine McGuinn4, Young Shil Park5, Oleksandra Stasyshyn6, Bulent Zulfikar7, Huyen Tran8, Werner Engl9, Srilatha D. Tangada10. 1Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom. 2University of Cincinnati College of Medicine and Cincinnati Children, Cincinnati, OH, USA. 3Bloodworks Northwest and the University of Washington, Seattle, WA, USA. 4Weill Cornell Medical College, New York, NY, USA. 5Kyung Hee University Hospital at Gangdong, Seoul, South Korea. 6Academy of Medical Sciences of Ukraine, Lviv. 7Department of Pediatric Hematology, Istanbul University Oncology Institute, Istanbul, Turkey. 8The Alfred Hospital, Melbourne, Australia. 9Baxalta Innovations GmbH, a Takeda company, Vienna, Austria. 10Baxalta US Inc, a Takeda company, Cambridge, MA, USA


20

COMBINED INHERITED AND ACQUIRED VON WILLEBRAND DISEASE: AN UNRECOGNIZED ENTITY
Maria DeSancho1, Kenneth Friedman2. 1Weill Cornell Medicine, New York, NY, USA. 2Blood Center of Wisconsin, Milwaukee, WI, USA


21

COMPARISON OF HEXAGONAL PHASE PHOSPHOLIPID NEUTRALIZATION ASSAYS FOR LUPUS ANTICOAGULANT DETECTION
Colin Douglas, Rachel Clarke, Navya Kesavan, Derek Lamont, Ali Sadeghi-Khomami, Amanda Wood, Karen Black. Precision BioLogic Inc, Dartmouth, NS, Canada


22

ANTI-TFPI ANTIBODY BAY 1093884: EARLY TERMINATION OF PHASE II STUDY DUE TO THROMBOSIS
Francesca Ferrante1, Sheila Ingham2, Marc Kunze3, Lisa A Michaels4. 1Bayer, Basel, Switzerland. 2Bayer, Sao Paulo, Brazil. 3Bayer, Berlin, Germany. 4Bayer, Whippany, NJ, USA


23

ASSESSMENT OF JOINT HEALTH USING POINT-OF-CARE ULTRASOUND IN WOMEN WITH BLEEDING DISORDERS
Kelli A Fraga, Rachel S Leeman, Joanna A Davis, Fernando F Corrales-Medina. University of Miami - Hemophilia Treatment Center, Miami, FL, USA


24

EFFICACY AND SAFETY OF “HALF-DOSE” DESMOPRESSIN FOR BLEEDING PROPHYLAXIS IN BLEEDING DISORDER PATIENTS UNDERGOING INVASIVE PROCEDURES
Fateeha Furqan1, Ronald Sham2, Peter Koiudes2. 1Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA. 2Department of Hematology and Oncology, Rochester General Hospital, Rochester, New York and the Mary M. Gooley Hemophilia Treatment Center of Rochester, Rochester, NY, USA


25

THROMBOSIS AND TRANSIENT ACQUIRED THROMBOPHILIA TRIGGERED BY EPSTEIN-BARR VIRUS IN PEDIATRICS
Jessica Garcia1, 2, Ayesha Zia1, 2. 1University of Texas Southwestern, Dallas, TX, USA. 2Children's Medical Center, Dallas, TX, USA


26

IDENTIFICATION AND CHARACTERIZATION OF A NOVEL THROMBOMODULIN LECTIN-LIKE DOMAIN VARIANT IN A PATIENT WITH VENOUS THROMBOSIS
Sean X. Gu1, Lauren M. Shevell2, Christopher A. Tormey1, Henry M. Rinder1, Noffar Bar2, 3, Alfred I. Lee2, 3. 1Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA. 2Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. 3Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA


27

DIFFERENTIAL DIAGNOSIS FOR SWELLING OF THE SCALP IN INFANCY
Michelle M Hallam1, Amy L Dunn1, 2. 1Nationwide Children's Hospital, Columbus, OH, USA. 2Ohio State University Wexner Medical Center, Columbus, OH, USA


28

DERMATOGLYPHIC TRAIT ASYMMETRY: A PREDICTING TOOL FOR SCREENING HEMOPHILIC PATIENTS IN GUYANA.
Ameet K. Jha1, Daniel J. Kanhai1, Michael Chapp3, Sujatha D'costa2. 1Texila American University, East Bank Demerara, Guyana. 2American University of Antigua, St. Johns, Antigua & Barbuda. 3Georgetown Public Hospital Corporation, Georgetown, Guyana


29

AN IDENTIFIED MUTATIONAL HOTSPOT IN TWO DIFFERENT EXONS OF FIBRINOGEN ALPHA GENE OF CONGENITAL FIBRINOGEN DEFICIENT PATIENTS.
Tehmina Khan1, Arshi Naz1, Anne Goodeve2, Shariq Ahmed1, Tahir Shamsi1, johannes Oldenburg3. 1NIBD, Karachi, Pakistan. 2University of Sheffield, sheffield, United Kingdom. 3Institute of experimental transfusions Medicine, Bonn, Germany


30

ORDER SET MODIFICATION PROMOTES EFFECTIVE LABORATORY TEST UTILIZATION IN THE DIAGNOSIS OF HIT
Michael Kimbrell1, 2, Matthew Butters2, Mikhail Akbashev2. 1University of Texas Southwestern, Dallas, TX, USA. 2Emory University School of Medicine, Atlanta, GA, USA


31

ACQUIRED HEMOPHILIA: CLINICAL CHARACTERISTICS AND BLEEDING OUTCOMES
Rohit Kumar1, Shruti Bhandari1, Sunny Singh2, Sindhu Malapati3. 1University of Louisville, Louisville, KY, USA. 2Henry Ford Cancer Institute, Detroit, MI, USA. 3Ascension St. John Hospital and Medical Center, Detroit, MI


32

HEMOSTASIOLOGICAL INDICATORS FOR DIAGNOSING PREECLAMPSIA IN PREGNANT WOMEN.
Bakhodir Kurbanov. Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan


33

DIGITAL MONITORING OF SERIOUS ADVERSE EVENTS SIGNALS IN PATIENTS WITH BLEEDING DISORDERS
Marc Lara1, Michael Callaghan2, Meera Chitlur2, Suchitra Acharya3, Joseph Stanco3, Guy Young4, Robert Sidonio5, Maissaa Janbain6, Amina Rafique6, Angela Kellum6, Cindy Leissinger6. 1MicroHealt, Inc, NY, NY, USA. 2Children's Hospital of Michigan, Detroit, MI, USA. 3Northwell Health, New Hydde Park, NY, USA. 4Children's Hospital of Los Angeles, Los Angeles, CA, USA. 5Children's Healthcare of Atlanta, Atlanta, GA, USA. 6Tulane University School of Medicine, New Orleans, LA, USA


34

BLEEDING PREDICTIONS FOR PATIENTS WITH HEMOPHILIA A USING MACHINE LEARNING.
Marc Lara1, Marcela Barrios2, Angela Kellum3, Jonathan Elliott2, Milena Almagro2. 1MicroHealth, Inc, New York, NY, USA. 2New York University. Department of Economics, New York, NY, USA. 3Tulane University School of Medicine, New Orleans, LA, USA


35

DIGITAL MONITORING OF PHYSICAL ACTIVITY VIA APP QUESTIONNAIRES IN PATIENTS WITH BLEEDING DISORDERS.
Marc Lara1, Suchitra Acharya2, Joseph Stanco2, Maissaa Janbain3, Amina Rafique3, Angela Kellum3, Robert Sidonio4, Guy Young5, Michael Callaghan6, Meera Chitlur6. 1MicroHealth, Inc, New York, NY, USA. 2Northwell Health, New York, NY, USA. 3Tulane University School of Medicine, New Orleans, LA, USA. 4Children's Healthcare of Atlanta, Atlanta, GA, USA. 5Children's Hospital of Los Angeles, Los Angeles, CA, USA. 6Children's Hospital of Michigan, Detroit, MI


36

DOES DISTANCE TO HEMOPHILIA TREATMENT CENTER IMPACT USE OF HEMOPHILIA TREATMENT SERVICES?
Susan U Lattimore, Alysia Cox, Kristina M Haley, Madolyn T Hofstetter, Kelsey Smith. Oregon Health a Science University, Portland, OR, USA


37

TAKE CONTROL. PERIOD. - NEEDS ASSESSMENT LEADING TO THE DEVELOPMENT OF A DIGITAL QUALITY IMPROVEMENT INTERVENTION DESIGNED TO ENHANCE ADHERENCE TO TRANEXAMIC ACID AND IRON SUPPLEMENTATION IN WOMEN WITH HEAVY MENSTRUAL BLEEDING
Ying Ling1, Filomena Meffe2, Deborah Robertson2, Jessica Petrucci3, Georgina Floros3, Paula James4, Jeffrey Mosko5, Michelle Sholzberg3, 6. 1Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Department of Obstetrics and Gynecology, St. Michael, Toronto, ON, Canada. 3Division of Hematology/Oncology, Department of Medicine, St. Michaels Hospital, Toronto, ON, Canada. 4Division of Hematology, Department of Medicine, Queen, Kingston, ON, Canada. 5Division of Gastroenterology, Department of Medicine, St. Michael, Toronto, ON, Canada. 66Department of Laboratory Medicine and Pathology, St. Michael, Toronto, ON, Canada


38

ENDOGENOUS THROMBIN POTENTIAL (ETP) IS SIGNIFICANTLY MORE ENHANCED BY EMICIZUMAB IN THROMBIN GENERATION ASSAY (TGA) PERFORMED WITH PLATELET RICH PLASMA (PRP) AS OPPOSED TO PLATELET POOR PLASMA (PPP)
Erika J Martin1, Gita V Massey2, Janice G Kuhn1. 1Virginia Commonwealth University, Richmond, VA, USA. 2Children, Richmond, VA, USA


39

LABORATORY CORRELATION OF THROMBIN GENERATION DATA, INCLUDING FACTOR VIII AND IX SENSITIVITIES ON AN AUTOMATED (ST GENESIA) VS. SEMI-AUTOMATED (CAT) PLATFORM
Steven Mcbryant1, Christian Nenninger1, Paul W Riley2, Mary Robinson1, Stefan Tiefenbacher1. 1Esoterix Inc. /Colorado Coagulation / A LabCorp Company (Laboratory Corporation of America Holdings), Englewood, CO, USA. 2Diagnostica Stago, Inc, Parsippany, NJ, USA


40

RAPID DESENSITIZATION AND SUBSEQUENT IMMUNE TOLERANCE INDUCTION IN A PATIENT WITH HYPERSENSITIVITY AND INHIBITOR TO FACTOR VIII
William B Mitchell. Children's Hospital at Montefiore, Bronx, NY, USA


41

DETERMINING PATHOGENICITY OF NOVEL VARIANTS FOUND IN BLEEDING/CLOTTING/PLATELET DISORDERS
Jihyun Moon, Jooeun Lim, Gayatri Raghuraman, Violet Votin, Bjorn Stromsness, James Kain, Mike Ero. Machaon Diagnostics, Inc, Oakland, CA, USA


42

AWARENESS AND MANAGEMENT OF BLEEDING DISORDER AMONGST DENTAL PRACTITIONERS IN ENUGU, SOUTH EAST, NIGERIA.
Helen C. Okoye1, Chilota C. Efobi2, Kaladada I. Korubo3, Anazoeze J. Madu1, Felix N. Chukwuneke4. 1Department of Haematology, College of Medicine, University of Nigeria Ituku Ozalla campus, Enugu, Nigeria. 2Department of Haematology and Blood Transfusion, College of Health Sciences, Nnamdi Azikiwe University Nnewi campus, Anambra, Nigeria. 3Department of Haematology and Blood Transfusion, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria. 4Department of Oral and Maxillofacial surgery, Faculty of Dentistry, College of Medicine, University of Nigeria, Ituku Ozalla campus Enugu Nigeria, Enugu, Nigeria


43

A RARE ETIOLOGY FOR WARFARIN SENSITIVITY IN A 28 YEAR OLD MALE
Natasha Pardy. Memorial University of Newfoundland, St. John's, NL, Canada


44

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA
K. John Pasi1, Claude Negrier2, Margaret V. Ragni3, Pencho Georgiev4, Vasily Mamonov5, Toshko Lissitchkov 6, Kichou Salim7, Baisong Mei7, Shauna Andersson7. 1Royal London Hospital Haemophilia Centre, Barts and The London School of Medicine and Dentistry, London, United Kingdom. 2Unite d, Lyon, France. 3Department of Medicine and Hemophilia Center of Western Pennsylvania, University of Pittsburgh, Pittsburgh, PA, USA. 4University Multiprofile Hospital for Active Treatment Sveti Georgi and Medical University Plovdiv, Plovdiv, Bulgaria. 5National Research Center for Hematology, Moscow, Russia. 6 Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria. 7Sanofi, Cambridge, MA, USA


45

NOVEL PRENATAL DIAGNOSIS OF PROTEIN C DEFICIENCY AND PRIMARY PROPHYLAXIS WITH PROTEIN C CONCENTRATE: A CASE SERIES.
Alexandra Prosser, Lauren Amos, Mukta Sharma. Children's Mercy Hospital, Kansas City, MO, USA


46

EFFICACY AND SAFETY RESULTS FROM A PHASE 3, RANDOMIZED, MULTICENTER STUDY OF RURIOCTOCOG ALFA PEGOL PHARMACOKINETIC-GUIDED PROPHYLAXIS TARGETING TWO FACTOR VIII TROUGH LEVELS IN PATIENTS WITH SEVERE HEMOPHILIA A (PROPEL STUDY): A CONSIDERATION FOR PERSONALIZED PROPHYLAXIS
Vlad C. Radulescu1, Robert Klamroth2, Jerzy Windyga3, Peter Collins4, Oleksandra Stasyshyn5, Hishamshah M. Ibrahim6, Werner Engl7, Srilatha D. Tangada8, Bruce Ewenstein8. 1University of Kentucky, Kentucky Children, Lexington, KY, USA. 2Vivantes Klinikum im Friedrichshain, Berlin Germany. 3Institute of Hematology and Transfusion Medicine, Warsaw, Poland. 4School of Medicine, Cardiff University, Cardiff, United Kingdom. 5Academy of Medical Sciences of Ukraine, Lviv, Ukrenia. 6Hospital Kuala Lumpur, Kuala Lumpur, Malaysia. 7Baxalta Innovations GmbH, a Takeda company, Vienna, Austria. 8Baxalta US Inc, a Takeda company, Cambridge, MA, USA


47

HEPARIN RESISTANCE IS COMMON IN PATIENTS ON EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
Vikram Raghunathan1, 2, Patricia Liu2, Joseph Shatzel1, 2, 3. 1Division of Hematology and Oncology, Oregon Health a Science University, Portland, OR, USA. 2Department of Medicine, Oregon Health a Science University, Portland, OR, USA. 3Department of Biomedical Engineering, Oregon Health a Science University, Portland, OR, USA


48

FAILURE OF MULTIPLE CONCURRENT ANTITHROMBOTIC AGENTS IN THE TREATMENT OF RECURRENT VENOUS THROMBOEMBOLISM IN A PATIENT WITH ELEVATED FACTOR VIII LEVELS
Bassil Said1, Mehul Patel2, Peter Kouides2. 1Rochester General Hospital, Department of Internal Medicine, Rochester, NY, USA. 2Rochester General Hospital, Lipson Cancer Center, Rochester, NY, USA


49

PULMONARY HEMORRHAGE AS A COMPLICATION OF TRANSPLANTATION-ASSOCIATED THROMBOTIC MICROANGIOPATHY: AN INSTITUTIONAL EXPERIENCE
Sarah Sartain 1, Stacey Shubert2, Caridad Martinez2. 1Department of Pediatrics, Section of Hematology-Oncology, Texas Children, Houston, TX, USA. 2Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children, Houston, TX, USA


50

EFFICACY AND SAFETY OF FIBRINOGEN CONCENTRATE FOR ON-DEMAND TREATMENT OF ACUTE BLEEDING AND SURGICAL PROPHYLAXIS IN PEDIATRIC PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY
Bruce. A Schwartz1, Flora Peyvandi2, Sunil. D Lohade3, Fulton D'Souza4, G. S Latha5, Claudia Khayat6, Omid Zekavat7, Irina Kruzkhova8, Cristina Solomon8, Sigurd Knaub8. 1Clinical Research a Development, Octapharma, Hoboken, NJ, USA. 2Fondazione IRCCS CaGrandaOspedaleMaggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy. 3Sahyadri Specialty Hospital, Pune, India. 4St. John, Bangalore, India. 5S. S Institute of Medical Science and Research Center, Davangere, India. 6Hotel De Dieu de France, Beirut, Lebanon. 7Nemazee Hospital Shiraz University of Medical Sciences, Shiraz, Iran. 8Research a Development Department, Octapharma, Lachen, Switzerland


51

SINGLE-DOSE PHARMACOKINETICS OF FIBRINOGEN CONCENTRATE FOR ON-DEMAND TREATMENT OF ACUTE BLEEDING AND SURGICAL PROPHYLAXIS IN PEDIATRIC PATIENTS WITH CONGENITAL FIBRINOGEN DEFICIENCY
Bruce. A Schwartz1, Flora Peyvandi2, S. D Lohade3, Fulton D'Souza4, G. S Latha5, Claudia Khayat6, Omid Zekavat7, Irina Kruzhkova8, Cristina Solomon8, Sigurd Knaub8. 1Clinical Research a Development, Octapharma, Hoboken, NJ, USA. 2Fondazione IRCCS CaGrandaOspedaleMaggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy. 3Sahyadri Specialty Hospital, Pune, India. 4St. John, Bangalore, India. 5S. S Institute of Medical Science and Research Center, Davangere, India. 6Hotel De Dieu de France, Beirut, Lebanon. 7Nemazee Hospital Shiraz University of Medical Sciences, Shiraz, Iran. 8Research a Development Department, Octapharma, Lachen, Switzerland


52

LABORATORY ASSESSMENT AND OPTIMIZATION OF A FVIII INHIBITOR ELISA KIT
Meera Sridharan, Katrina McGaffey, Julie Tange, Dong Chen , Rajiv Pruthi . Mayo Clinic, Rochester, MN, USA


53

IMPLEMENTING GOAL-HēM, A GOAL ATTAINMENT SCALING INSTRUMENT
Justin Stanley1, Taylor Dunn1, Jorge Caicedo2, Michael Denne2, Jonathan Roberts3, Kenneth Rockwood1, 4. 1DGI Clinical Inc, Halifax, NS, Canada. 2Baxalta US Inc, a Takeda company, Cambridge, MA, USA. 3Bleeding a Clotting Disorders Institute, Peoria, IL, USA. 4Dalhousie University, Halifax, NS, Canada


54

A NOVEL PATHOGENIC VARIANT WITHIN THE FACTOR XIII ACTIVE SITE PRESENTING AS SEVERE UMBILICAL HEMORRHAGE
Kaitlin L. Strumph, Jennifer G. Davila, William B. Mitchell. Division of Hematology/Oncology, The Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA


55

INDEPENDENT EVALUATION OF A NEW CHROMOGENIC FACTOR VIII ASSAY KIT
Julie I. Tange, Nahla Heikal, Dong Chen, Rajiv Pruthi. Comprehensive Hemophilia Center and Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA


56

RAPID DIAGNOSIS OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) USING A NEW FULLY-AUTOMATED CHEMILUMINESCENT ASSAY FOR ADAMTS13 ACTIVITY.
Pierre A Toulon1, Ines Harzallah2. 1Pasteur University Hospital, Hematology, Nice, France. 2Regional Hospital, Hematology, Mulhouse, France


57

THE HEMOSTATIC AND FIBRINOLYTIC ABNORMALITIES IN TRAUMA-INDUCED COAGULOPATHY
Mark Walsh, MD1, Hau C. Kwaan, MD2, Jordan Hatch, BS3, Faran Bokhari, MD, FACS4, Scott Thomas, MD5. 1St. Joseph Regional Medical Center, Mishawaka, IN, USA. 2Division of Hematology-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 3Indiana University School of Medicine, South Bend, IN, USA. 4John H. Stroger, Jr. Hospital, Chicago, IL, USA. 5Beacon Health Systems, South Bend, IN, USA


58

UTILIZATION OF TELEMEDICINE FOR COMPREHENSIVE VISITS IN PATIENTS WITH INHERITED BLEEDING DISORDERS DURING THE COVID-19 PANDEMIC
Cassandra P Wang1, Kelly A Bush2, Rosalie Brooks2, Katharine Farrow2, Lizandra Gilsdorf2, Fernanda Cortez2, Courtney D Thornburg2. 1Department of Pediatrics, University of California-San Diego School of Medicine, La Jolla, CA, USA. 2Division of Pediatric Hematology/Oncology, Rady Children's Hospital, San Diego, San Diego, CA, USA


59

PREPARATION OF A NATIONAL RESEARCH AGENDA FOR THE INHERITED BLEEDING DISORDERS COMMUNITY
Michelle L. Witkop1, Michael Recht2, Donna DiMichele3, Leonard A. Valentino1. 1National Hemophilia Foundation, New York, NY, USA. 2American Thrombosis and Hemostasis Network, Rochester, NY, USA. 3Donna DiMichele Consulting, LLC, Washington, DC, USA


60

PULMONARY VEIN THROMBOSIS ASSOCIATED WITH A LARGE HIATAL HERNIA
Yu Zhao, Reynold Andika, Richard Alweis. Rochester Regional Health/Unity Hospital, Rochester, NY, USA